pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 1·1 min read
save

Samsung Biologics workers launch five-day strike over wage dispute

May 1, 2026·read at Endpoints ↗Negative

On May 1, 2026 union workers at Samsung Biologics began a five-day strike after a rally in April.

The walkout is over wage negotiations, with about 95% of the company's union members voting in favor of striking.

The strike at the Bio Campus in Songdo, Incheon may disrupt the company's manufacturing operations.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Samsung Biologics workers begin five-day strike over wage disputes”

read at Endpoints ↗
95 words · retrieved May 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoRapport says drug it licensed from J&J clears Phase 2 bipolar mania studyEndpoints
  • 17h agoFormer MIT professor David Sabatini awarded $6M in defamation caseEndpoints
  • 17h agoAntheia gets $80M conditional DOD loan to onshore to the USEndpoints
  • 19h ago#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and moreEndpoints
  • 21h agoGilead’s pill posts stronger colitis remission rates than EntyvioEndpoints